- Home
- BUSE vs NVCR Comparison
BUSE vs NVCR Comparison
Compare BUSE & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUSE
- NVCR
- Stock Information
- Founded
- BUSE 1868
- NVCR 2000
- Country
- BUSE United States
- NVCR Switzerland
- Employees
- BUSE N/A
- NVCR N/A
- Industry
- BUSE Major Banks
- NVCR Medical/Dental Instruments
- Sector
- BUSE Finance
- NVCR Health Care
- Exchange
- BUSE Nasdaq
- NVCR Nasdaq
- Market Cap
- BUSE 1.9B
- NVCR 1.9B
- IPO Year
- BUSE N/A
- NVCR 2015
- Fundamental
- Price
- BUSE $22.12
- NVCR $19.11
- Analyst Decision
- BUSE Buy
- NVCR Buy
- Analyst Count
- BUSE 5
- NVCR 6
- Target Price
- BUSE $27.80
- NVCR $32.83
- AVG Volume (30 Days)
- BUSE 433.4K
- NVCR 941.3K
- Earning Date
- BUSE 07-22-2025
- NVCR 07-24-2025
- Dividend Yield
- BUSE 4.52%
- NVCR N/A
- EPS Growth
- BUSE N/A
- NVCR N/A
- EPS
- BUSE 0.95
- NVCR N/A
- Revenue
- BUSE $430,476,000.00
- NVCR $621,711,000.00
- Revenue This Year
- BUSE $62.50
- NVCR $5.56
- Revenue Next Year
- BUSE $12.41
- NVCR $9.15
- P/E Ratio
- BUSE $23.16
- NVCR N/A
- Revenue Growth
- BUSE 0.48
- NVCR 18.27
- 52 Week Low
- BUSE $18.40
- NVCR $14.17
- 52 Week High
- BUSE $28.97
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- BUSE 54.10
- NVCR 58.46
- Support Level
- BUSE $21.41
- NVCR $18.66
- Resistance Level
- BUSE $22.31
- NVCR $20.06
- Average True Range (ATR)
- BUSE 0.40
- NVCR 0.86
- MACD
- BUSE -0.04
- NVCR 0.19
- Stochastic Oscillator
- BUSE 46.41
- NVCR 71.98
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.